BACKGROUND AND AIMS: Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. METHODS: The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. RESULTS: In total, 2154 patients were enrolled from the Czech Republic (n = 509), Hungary (n = 319), Poland (n = 460), Romania (n = 259), Slovakia (n = 123) and Ukraine (n = 484). At LDL-C measurement, most patients were on either moderate- or high-intensity statin monotherapy (53% and 32%, respectively). Despite this, only 44% of patients achieved risk-based LDL-C goals recommended by the 2016 ESC/EAS guidelines, ranging from 21% in Ukraine to 50% in Hungary and Romania. Only 24% of patients overall achieved the risk-based LDL-C goals recommended by the 2019 ESC/EAS guidelines, ranging from 11% in Ukraine to 32% in Poland. CONCLUSIONS: Among patients receiving lipid-lowering therapy, more than half did not achieve their 2016 LDL-C goals. In one of the first comparative analyses evaluating 2019 risk-based goal attainment among countries in CEE, three-quarters of patients did not meet their 2019 LDL-C goals, highlighting a significant gap between guidelines and clinical practice for lipid management in CEE.

3rd Department of Internal Medicine General University Hospital and Charles University 12808 Prague 2 Czech Republic

Amgen Sro 110 02 Prague 1 Czech Republic

Coordination Center for Familial Hyperlipidemia Slovak Medical University 833 03 Bratislava Slovakia

Department of Family Medicine and Public Health Faculty of Medicine University of Opole 45 040 Opole Poland

Department of Hypertension Chair of Nephrology and Hypertension Medical University of Lodz 90 419 Lodz Poland; Polish Mother's Memorial Hospital Research Institute 93 338 Lodz Poland; Cardiovascular Research Centre University of Zielona Góra 65 417 Zielona Góra Poland

Emergency Cardiology Department National Scientific Center M D Strazehesko Institute of Cardiology 03680 Kiev Ukraine

Global Biostatistical Science Amgen Ltd 240 Cambridge Science Park Milton Road Cambridge CB4 0WD UK

Hungarian Army Medical Center Budapest 1134 Hungary

Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit Imperial College London Stadium House 68 Wood Lane London W12 7RH UK

Institute of Cardiovascular Diseases Cardioprevent Foundation Victor Babes University of Medicine and Pharmacy Timisoara Timisoara 300041 Romania

Institute of General Practice Charles University 128 00 Prague 2 Czech Republic

Citace poskytuje Crossref.org

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)

Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study